JILIN AODONG(SZ:000623) Zheng Quan Ri Bao·2026-02-12 12:36Group 1 - Jilin Aodong Pharmaceutical Group Co., Ltd. announced that its subsidiary, Yanbian Pharmaceutical Co., Ltd., has obtained 10 "Traditional Chinese Medicine Formula Granule Listing Filing Certificates" [2] - Jilin Aodong is focusing on the development of traditional Chinese medicine formula granules in key regions and medical institutions, primarily targeting grade A hospitals while utilizing three terminals and online platforms for clinical promotion [2] - Yanbian Pharmaceutical has completed its pre-processing workshop, extraction workshop, formulation workshop, and comprehensive R&D building, with multiple production lines passing GMP compliance checks as of January 23, 2025 [2] Group 2 - Jilin Aodong will continue to implement a "pharmaceutical health + financial capital" dual-drive strategy, enhancing the synergy between industry and finance [3] - The company aims to leverage its strong pharmaceutical industry foundation, mature product matrix, and solid market competitive advantages to establish a sustainable development base [3] - Investment returns from financial activities will be reinvested into pharmaceutical R&D, production, and industry chain upgrades, fostering a positive collaboration with the pharmaceutical sector [3]